Device Trial Radar · NCT05339126
RNS System LGS Feasibility Study
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 4, 2022
Primary completion
Nov 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- NeuroPaceNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS); University of Florida
- First posted
- Apr 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.
Conditions
- Epilepsy
- Lennox Gastaut Syndrome
- Lennox-Gastaut Syndrome, Intractable
- Seizures
- Seizures, Generalized
Interventions
RNS SystemDevice
The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Annual device-related serious adverse event (SADE) rateTime frame: 12 months post-implant
- Safety: Annual device-related serious adverse event (SADE) rateTime frame: 24 months post-implant
- Effectiveness: Blinded evaluation period (BEP) responder rateTime frame: 12 months post-implant
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.